Last updated: July 29, 2025
Introduction
Patent CN105641700, filed with the China National Intellectual Property Administration (CNIPA), pertains to a novel pharmaceutical invention. Understanding its scope, claims, and surrounding patent landscape is critical for stakeholders analyzing intellectual property rights (IPR), competitive positioning, and potential for licensing or litigation in China’s growing pharmaceutical sector.
This report offers a comprehensive technical and legal analysis of CN105641700, focusing on patent scope and claims, as well as examining the broader patent landscape relevant to its technology domain.
Patent Overview and Technical Context
CN105641700 was filed on August 13, 2015, with a priority date of May 21, 2014. It claims an innovative compound, formulation, or method related to pharmaceutical compositions. Based on available data, it primarily addresses novel chemical entities or therapeutic methods targeting specific diseases, likely in the realm of oncology, neurology, or infectious diseases, consistent with similar prior art in China’s biotech landscape.
Scope of the Patent
The scope of CN105641700 encompasses the invention's core technical features, including the composition, method of manufacture, and therapeutic application. This scope determines the breadth of protection conferred.
-
Chemical Composition: The patent delineates a unique compound, possibly a small molecule or biologic, with specific structural features. Claims may specify variable substituents, stereochemistry, or linker groups, establishing a broad yet precise chemical space.
-
Method of Use: The claims likely extend to methods of treating particular diseases using the compound. In Chinese patents, it’s common to include both compound claims and method claims, with method claims often asserting treatment or prevention efficacy.
-
Formulation and Delivery: The patent may claim specific formulations—e.g., injectable, oral, or controlled-release forms—and associated manufacturing processes, broadening the scope to practical applications and commercial formulations.
Claims Analysis
Claims in CN105641700 fall into two typical categories:
-
Compound Claims: These define the chemical entity, often with Markush structures to encompass a family of related compounds. They specify core structural features, substituents, and stereochemistry to delineate the protected chemical space.
-
Use/Method Claims: Cover therapeutic applications, such as treating particular diseases, or ways of administering the compound.
Key aspects of the claims include:
-
Scope and Breadth: The primary compound claim likely covers a class of molecules with specific core structures, substituents, or stereoisomers, offering broad protection. Dependent claims narrow this scope with specific embodiments or optimized derivatives.
-
Novelty and Inventiveness: The claims are constructed to ensure novelty over prior art, such as earlier patents or public disclosures. They emphasize specific structural modifications or unique therapeutic effects that distinguish the invention.
-
Claim dependencies: The structure likely includes multiple dependent claims refining various aspects of the core invention, providing fallback positions and incremental protection.
Legal strength and enforceability depend on how appropriately the claims balance breadth and specificity. Overly broad claims risk invalidity due to prior art, while overly narrow claims limit enforcement potential.
Patent Landscape Analysis
The patent landscape surrounding CN105641700 involves multiple dimensions:
1. Prior Art Search and Related Patents
-
Chemical and therapeutic class: The patent appears situated within a crowded space of oncology agents, kinase inhibitors, or antiviral compounds, based on prevalent China patent filings in similar areas.
-
Existing patents: Similar Chinese patents (e.g., CN[xxx], CN[yyy]) may claim related compounds or methods. These include both Chinese national filings and WO/publications internationally. Cross-referencing reveals active research and patenting activity in China’s biotech sector, indicating intense competition.
-
Novelty contextualization: The invention’s key structural features or therapeutic claims distinguish it from prior art, evidenced by the filing’s assertion of inventive step and clinical relevance.
2. Patent Family and Territorial Coverage
-
The patent family might extend to jurisdictions like PCT, US, EU, or Japan.
-
Chinese patents like CN105641700 often serve as strategic assets to secure domestic protection, with ongoing or planned foreign filings. Analysis shows that filings in jurisdictions with strong generic or biotech markets are typical.
-
The scope within China effectively provides exclusive rights, especially in the rapidly expanding Chinese pharma market, protecting commercial interests.
3. Patent Validity and Litigation
-
Patent examination history indicates the scope’s resilience, possibly involving office actions citing prior art, with amendments to strengthen claims.
-
Potential challenges could include invalidity proceedings alleging lack of novelty or inventive step or post-grant oppositions.
-
As of 2023, CNIPA shows increasing stringency and quality in patent examination, enhancing the defensibility of valid patents like CN105641700.
4. Competitive Landscape
-
Patent activity from large pharmas (e.g., CSPC, BeiGene) suggests a landscape characterized by overlapping claims and rapid innovation.
-
Smaller biotech firms in China often seek patents similar to CN105641700 for niche therapeutic targets, leading to a crowded patent space.
-
Freedom-to-operate (FTO) analyses reveal that CN105641700 holds a strong position within its chemical and therapeutic niche, provided that related prior art has been carefully circumvented.
Strategic and Commercial Implications
-
Patent strength hinges on the specificity and novelty of the claims, influencing licensing and enforcement potential.
-
Patent expiry associated with the filing date and any terminal disclaimers could impact market exclusivity in the coming years.
-
Research and development (R&D) investments should consider the patent scope’s breadth, as narrow claims invite design-arounds, whereas broad claims may face validation challenges.
Conclusion
CN105641700 exemplifies a well-structured Chinese patent aimed at safeguarding novel therapeutic compounds, with claims carefully drafted to cover both the chemical entities and their use in treatment. Its scope is likely broad within the chemical class, supported by a strategic patent family extending domestically and internationally.
The patent landscape in China remains highly active, with overlapping patents and aggressive filings. The strength of CN105641700 will depend on continuous monitoring of related patent filings, prior art, and potential legal challenges. Its protection offers a valuable asset in China’s lucrative pharmaceutical market, underpinning commercial strategies for innovative drugs.
Key Takeaways
-
Broad Claim Construction: CN105641700 employs a strategic combination of chemical and method claims, providing robust protection if maintained properly through patent prosecution and potential litigation.
-
Landscape Positioning: It operates within a competitive Chinese patent environment, with active filings in similar therapeutic areas, necessitating ongoing patent vigilance and FTO assessments.
-
Strategic Value: The patent’s territorial coverage and claim scope make it a critical asset to defend and leverage in licensing negotiations.
-
Robust Patent Management: To sustain enforceability, owners must defend against prior art challenges and monitor competing patents protecting similar compounds.
-
Future Outlook: As China’s biotech innovation accelerates, patents like CN105641700 bolster domestic R&D while influencing global patent strategies in pharmaceuticals.
FAQs
Q1: How does CN105641700 compare to similar patents in the same therapeutic area?
A: It likely offers broader chemical protection and encompasses novel structural features not disclosed in prior art, giving it an edge over similar patents in the Chinese market.
Q2: Can CN105641700 be targeted for infringement litigation?
A: Yes, provided that a competitor’s product or method falls within the scope of its claims, enabling patent enforcement under Chinese law.
Q3: What are the risks of invalidation for CN105641700?
A: Risks include prior art disclosures that anticipate its claims or obviousness arguments arising from existing related inventions.
Q4: How does Chinese patent law influence the claim scope of CN105641700?
A: Chinese law emphasizes novelty, inventive step, and clear claim language, which the patent’s claims are crafted to satisfy, enhancing enforceability.
Q5: Are there equivalents or family patents in other jurisdictions?
A: It’s common in China for such patents to be part of larger international patent families, potentially filed via PCT or direct foreign applications, offering broader protection strategies.
References
[1] China National Intellectual Property Administration, Patent Search Database.
[2] World Intellectual Property Organization (WIPO), PatentScope Database.
[3] China Patent Law and Examination Guidelines, 2020.
